EE04578B1 - Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nendesolvaatide suu kaudu manustamiseks - Google Patents

Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nendesolvaatide suu kaudu manustamiseks

Info

Publication number
EE04578B1
EE04578B1 EEP199900441A EEP9900441A EE04578B1 EE 04578 B1 EE04578 B1 EE 04578B1 EE P199900441 A EEP199900441 A EE P199900441A EE P9900441 A EEP9900441 A EE P9900441A EE 04578 B1 EE04578 B1 EE 04578B1
Authority
EE
Estonia
Prior art keywords
piperidino
solvates
salts
pharmaceutical composition
oral administration
Prior art date
Application number
EEP199900441A
Other languages
English (en)
Estonian (et)
Inventor
Abramovici Bernard
Condamine Christian
Gromenil Jean-Claude
Original Assignee
Sanofi-Synthlabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthlabo filed Critical Sanofi-Synthlabo
Publication of EE9900441A publication Critical patent/EE9900441A/xx
Publication of EE04578B1 publication Critical patent/EE04578B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP199900441A 1997-03-28 1998-03-27 Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nendesolvaatide suu kaudu manustamiseks EE04578B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9703835A FR2761266B1 (fr) 1997-03-28 1997-03-28 Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
PCT/FR1998/000631 WO1998043636A1 (fr) 1997-03-28 1998-03-27 Composition pharmaceutique pour administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs s olvates

Publications (2)

Publication Number Publication Date
EE9900441A EE9900441A (et) 2000-04-17
EE04578B1 true EE04578B1 (et) 2006-02-15

Family

ID=9505295

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900441A EE04578B1 (et) 1997-03-28 1998-03-27 Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nendesolvaatide suu kaudu manustamiseks

Country Status (41)

Country Link
US (1) US6893659B2 (sk)
EP (1) EP0969832B1 (sk)
JP (1) JP3805797B2 (sk)
KR (1) KR100479521B1 (sk)
CN (1) CN1126543C (sk)
AR (1) AR012160A1 (sk)
AT (1) ATE202703T1 (sk)
AU (1) AU740486B2 (sk)
BR (1) BR9808429A (sk)
CA (1) CA2284051C (sk)
CO (1) CO4950527A1 (sk)
CY (2) CY2275B1 (sk)
CZ (1) CZ292129B6 (sk)
DE (1) DE69801045T2 (sk)
DK (1) DK0969832T3 (sk)
DZ (1) DZ2453A1 (sk)
EE (1) EE04578B1 (sk)
ES (1) ES2161049T3 (sk)
FR (1) FR2761266B1 (sk)
GR (1) GR3036382T3 (sk)
HK (1) HK1022831A1 (sk)
HR (1) HRP980163B1 (sk)
HU (1) HU224838B1 (sk)
ID (1) ID22973A (sk)
IL (1) IL131818A (sk)
IS (1) IS1960B (sk)
MY (1) MY121733A (sk)
NO (1) NO321615B1 (sk)
NZ (1) NZ337736A (sk)
PL (1) PL191107B1 (sk)
PT (1) PT969832E (sk)
RS (1) RS49606B (sk)
RU (1) RU2193886C2 (sk)
SA (1) SA98190095B1 (sk)
SI (1) SI0969832T1 (sk)
SK (1) SK283265B6 (sk)
TR (1) TR199902236T2 (sk)
TW (1) TW565450B (sk)
UA (1) UA49056C2 (sk)
WO (1) WO1998043636A1 (sk)
ZA (1) ZA982609B (sk)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1353696T3 (da) * 2001-01-26 2007-04-10 Schering Corp Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivator(er) og sterolabsorptionsinhibitor(er) og behandlinger til vaskulære indikationer
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1556373A1 (en) * 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
JP4041153B2 (ja) * 2003-05-07 2008-01-30 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドとその使用
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
WO2006025069A2 (en) 2004-07-12 2006-03-09 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2006052608A2 (en) 2004-11-01 2006-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
RU2007123366A (ru) * 2004-11-24 2008-12-27 Мерк Энд Ко. Жидкие и полутвердые фармацевтические препаративные формы для перорального введения замещенного амида
JP2008523684A (ja) * 2004-12-07 2008-07-03 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ インテリジェントポースボタン
DK1868999T3 (da) 2005-04-06 2009-08-17 Hoffmann La Roche Pyridin-3-carboxamidderivater som omvendte CB1-agonister
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP1745783A1 (en) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
ES2348374B1 (es) * 2005-07-15 2011-08-02 Laboratorios Del Dr Esteve, S.A. Formulaciones farmaceuticas orales que comprenden compuestos de pirazolina sustituidos.
EP1743637A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2007009682A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Oral pharmaceutical formulations comprising substituted pyrazoline compounds
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7875633B2 (en) 2005-08-24 2011-01-25 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
AU2006312557B2 (en) 2005-11-10 2011-12-08 Msd K.K. Aza-substituted spiro derivative
US7786144B2 (en) 2006-05-31 2010-08-31 Solvay Pharmaceuticals B.V. Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
CA2650622A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals B.V. Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
FR2913018A1 (fr) * 2007-02-23 2008-08-29 Sanofi Aventis Sa Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
FR2919868A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n,n-dimethyformamide de rimonabant, et son procede de preparation
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
CA2727914A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
IT1390848B1 (it) * 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8592457B2 (en) 2008-10-30 2013-11-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
IT1393930B1 (it) * 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1395724B1 (it) 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
IT1396951B1 (it) * 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
PE20140859A1 (es) 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
BR112015002080A2 (pt) 2012-08-02 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme BICYCLIC ANTIDIABETIC COMPOUNDS
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
TWI767945B (zh) 2016-10-14 2022-06-21 義大利商Ｔｅｓ製藥（股份）責任有限公司 α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
US10554908B2 (en) * 2016-12-05 2020-02-04 Facebook, Inc. Media effect application
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
US10562896B2 (en) 2017-05-31 2020-02-18 Chemocentryx, Inc. 6-5 fused rings as C5a inhibitors
US20190300526A1 (en) * 2018-04-02 2019-10-03 Chemocentryx, Inc. PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
SG11202104550WA (en) 2018-11-20 2021-05-28 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4200295A1 (en) 2020-08-18 2023-06-28 Merck Sharp & Dohme LLC Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR656354A (fr) * 1927-11-07 1929-05-07 British Maxium Ltd Procédé de purification des métaux
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
US5087454A (en) * 1990-07-30 1992-02-11 American Home Products Corporation Ibuprofen tablet
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof

Also Published As

Publication number Publication date
CY2006005I2 (el) 2009-11-04
CN1126543C (zh) 2003-11-05
HRP980163A2 (en) 1998-12-31
RU2193886C2 (ru) 2002-12-10
MY121733A (en) 2006-02-28
ID22973A (id) 1999-12-23
PL335942A1 (en) 2000-05-22
ATE202703T1 (de) 2001-07-15
IS5190A (is) 1999-09-23
SK283265B6 (sk) 2003-04-01
AU740486B2 (en) 2001-11-08
CZ292129B6 (cs) 2003-08-13
CZ344199A3 (cs) 2000-01-12
ES2161049T3 (es) 2001-11-16
CA2284051A1 (en) 1998-10-08
RS49606B (sr) 2007-06-04
AU7052798A (en) 1998-10-22
UA49056C2 (uk) 2002-09-16
HK1022831A1 (en) 2000-08-25
FR2761266B1 (fr) 1999-07-02
CN1251524A (zh) 2000-04-26
SK130999A3 (en) 2000-03-13
TW565450B (en) 2003-12-11
HRP980163B1 (en) 2002-10-31
ZA982609B (en) 1998-09-30
EE9900441A (et) 2000-04-17
PT969832E (pt) 2001-11-30
EP0969832B1 (fr) 2001-07-04
AR012160A1 (es) 2000-09-27
CY2006005I1 (el) 2009-11-04
DZ2453A1 (fr) 2004-07-14
CY2275B1 (en) 2003-07-04
KR20010005752A (ko) 2001-01-15
KR100479521B1 (ko) 2005-03-30
IS1960B (is) 2004-11-15
BR9808429A (pt) 2000-05-23
FR2761266A1 (fr) 1998-10-02
WO1998043636A1 (fr) 1998-10-08
JP2001517224A (ja) 2001-10-02
IL131818A (en) 2003-07-31
PL191107B1 (pl) 2006-03-31
HUP0001894A3 (en) 2002-01-28
NO321615B1 (no) 2006-06-12
DE69801045D1 (de) 2001-08-09
NO994706D0 (no) 1999-09-27
DE69801045T2 (de) 2002-03-14
TR199902236T2 (xx) 1999-12-21
CA2284051C (en) 2005-01-11
EP0969832A1 (fr) 2000-01-12
YU47099A (sh) 2002-06-19
NZ337736A (en) 2001-02-23
US20030003145A1 (en) 2003-01-02
IL131818A0 (en) 2001-03-19
JP3805797B2 (ja) 2006-08-09
SI0969832T1 (sk) 2001-12-31
NO994706L (no) 1999-11-25
HU224838B1 (en) 2006-03-28
CO4950527A1 (es) 2000-09-01
SA98190095B1 (ar) 2006-06-18
DK0969832T3 (da) 2001-10-22
GR3036382T3 (en) 2001-11-30
US6893659B2 (en) 2005-05-17
HUP0001894A2 (hu) 2001-04-28

Similar Documents

Publication Publication Date Title
EE9900441A (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nende solvaatide suu kaudu manustamiseks
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
ITMI950529A0 (it) Composizioni farmaceutiche e procedimento per la loro preparazione
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
PT998272E (pt) Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol
EE9800426A (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200200281A (et) Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
PT868911E (pt) Formulacoes de rapamicina para administracao oral
EE200000651A (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
NO950134D0 (no) Formuleringer for oralt administrerte farmasöytiske midler
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
EE9900206A (et) N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
NO996044L (no) Rapamycinformuleringer for oral administrasjon
IL127518A (en) Substituted heterocyclic benzocycloalkenes, their preparation and pharmaceutical compositions having an analgesic effect
BR9607433A (pt) Composição farmacêutica para administração parental
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
EE200000336A (et) Ehhinokandiini derivaadid, nende valmistamismeetod, vaheühendid ja farmatseutilised kompositsioonid
FI972129A0 (fi) 6-metoksi-1H-bentsotriatsoli-5-karboksamidijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä lääkekoostumuksia
EE200100592A (et) 14ß-H-steroolid, neid sisaldavad farmatseutilisedkompositsioonid ja nende derivaatide kasutamine meioosi reguleerivate ravimite valmistamiseks

Legal Events

Date Code Title Description
HC1A Change of owner name
AA1Y Spc filed

Free format text: PRODUCT NAME: ACOMPLIA - RIMONABANT; REG NO/DATE: EU/1/06/344/001 19.06.2006 EU/1/06/344/002 19.06.2006 EU/1/06/344/003 19.06.2006 EU/1/06/344/004

Spc suppl protection certif: C20060001

Filing date: 20060822

FG1Y Spc granted

Free format text: PRODUCT NAME: ACOMPLIA - RIMONABANT; REG NO/DATE: EU/1/06/344/001 19.06.2006 EU/1/06/344/002 19.06.2006 EU/1/06/344/003 19.06.2006 EU/1/06/344/004

Spc suppl protection certif: C20060001 00011

Filing date: 20060822

Extension date: 20210619

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MC1Y Annulment of an spc

Spc suppl protection certif: 00011

MM4A Lapsed by not paying the annual fees

Effective date: 20140327